Neuroblastoma: Molecular pathogenesis and therapy

Annual Review of Medicine

Volumn 66, Issue , 2015, Pages 49-63

  Louis, Chrystal U ^a,b   Shohet, Jason M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

cancer biology; epigenetics; epithelial to mesenchymal transition; neural crest development; neuroblastoma; oncogenes; pediatric cancer

Indexed keywords

UNTRANSLATED RNA;

ARTICLE; CANCER STAGING; CARCINOGENESIS; CHILDHOOD CANCER; CHROMATIN IMMUNOPRECIPITATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE TRANSLOCATION; HETEROZYGOSITY LOSS; HIGH RISK POPULATION; HIGH THROUGHPUT SEQUENCING; HIRSCHSPRUNG DISEASE; HUMAN; MOLECULAR PATHOLOGY; NEURAL CREST; NEURAL CREST CELL; NEUROBLASTOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; ADOLESCENT; CHILD; EMBRYOLOGY; INFANT; METABOLISM; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; INFANT; INFANT, NEWBORN; NEURAL CREST; NEUROBLASTOMA;

EID: 84921417441     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-011514-023121     Document Type: Article

References (95)

1. CDC. U.S. Cancer Statistics Working Group. 2013. United States Cancer Statistics: 1999-2010 incidence and mortality web-based report. US Dep. HealthHum. Serv., Cent. Disease Control Prev. andNatl. Cancer Inst.
2. London WB, Castleberry RP, Matthay KK, et al. 2005. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J. Clin. Oncol. 23:6459-65
3. Monclair T, Brodeur GM, Ambros PF, et al. 2009. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J. Clin. Oncol. 27:298-303
4. Park JR, Bagatell R, London WB, et al. 2013. Children's Oncology Group's 2013 blueprint for research: neuroblastoma. Pediatr. Blood Cancer 60:985-93
5. Yu AL. 2014. Update on outcome for high-risk neuroblastoma treated on a randomized trial of chimeric anti-gd2 antibody (ch14.18) + GM-CSF/IL2 in first response: a Children's Oncology Group study. Presented at Advances in Neuroblastoma Res. Conf. (ANR2014), Cologne
6. Betters E, Liu Y, Kjaeldgaard A, et al. 2010. Analysis of early human neural crest development. Dev. Biol. 344:578-92
7. Fredlund E, RingnerM, Maris JM, Pahlman S. 2008. High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc. Natl. Acad. Sci. USA 105:14094-99
8. Takahashi Y, Sipp D, Enomoto H. 2013. Tissue interactions in neural crest cell development and disease. Science 341:860-63
9. Hall BK. 2000. The neural crest as a fourth germ layer and vertebrates as quadroblastic not triploblastic. Evol. Dev. 2:3-5
10. Prasad MS, Sauka-Spengler T, Labonne C. 2012. Induction of the neural crest state: control of stem cell attributes by gene regulatory, post-Transcriptional and epigenetic interactions. Dev. Biol. 366:10-21
11. MayanilCS. 2013. Transcriptional and epigenetic regulation of neural crest induction during neurulation. Dev. Neurosci. 35(5):361-72
12. Strobl-Mazzulla PH, BronnerME. 2012. Epithelial to mesenchymal transition: new and old insights from the classical neural crest model. Semin. Cancer Biol. 22(5-6):411-16
13. Pegoraro C, Monsoro-Burq AH. 2013. Signaling and transcriptional regulation in neural crest specification and migration: lessons from xenopus embryos. Wiley Interdiscip. Rev. Dev. Biol. 2:247-59
14. Shtukmaster S, Schier MC, Huber K, et al. 2013. Sympathetic neurons and chromaffin cells share a common progenitor in the neural crest in vivo. Neural Dev. 18(8):12
15. Denecker G, Vandamme N, Akay O, et al. 2014. Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ. 21(8):1250-61
16. Powell DR, Hernandez-Lagunas L, LaMonica K, Artinger KB. 2013. Prdm1a directly activates foxd3 and tfap2a during zebrafish neural crest specification. Development 140:3445-55
17. Hernandez-Lagunas L, Powell DR, Law J, et al. 2011. prdm1a and olig4 act downstream of Notch signaling to regulate cell fate at the neural plate border. Dev. Biol. 356:496-505
18. Rogers CD, Saxena A, Bronner ME. 2013. Sip1 mediates an E-cadherin-To-N-cadherin switch during cranial neural crest EMT. J. Cell Biol. 203:835-47
19. Beck B, Blanpain C. 2013. Unravelling cancer stem cell potential. Nat. Rev. Cancer 13:727-38
20. Howk CL, Voller Z, Beck BB, Dai D. 2013. Genetic diversity in normal cell populations is the earliest stage of oncogenesis leading to intra-Tumor heterogeneity. Front. Oncol. 5(3):61
21. Hsu DM, Agarwal S, Benham A, et al. 2013. G-CSF receptor positive neuroblastoma subpopulations are enriched in chemotherapy-resistant or relapsed tumors and are highly tumorigenic. Cancer Res. 73:4134-46
22. Nuchtern JG, London WB, Barnewolt CE, et al. 2012. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann. Surg. 256:573-80
23. Strother DR, London WB, Schmidt ML, et al. 2012. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J. Clin. Oncol. 30:1842-48
24. Rinon A, Molchadsky A, Nathan E, et al. 2011. p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes. Development 138:1827-38
25. Chen Z, Lin Y, Barbieri E, et al. 2009. Mdm2 deficiency suppresses MYCN-driven neuroblastoma tumorigenesis in vivo. Neoplasia 11:753-62
26. Kim E, Shohet J. 2009. Targeted molecular therapy for neuroblastoma: the ARF/MDM2/p53 axis. J. Natl. Cancer Inst. 101:1527-29
27. Pugh TJ, Morozova O, Attiyeh EF, et al. 2013. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45:279-84
28. Fujita T, Igarashi J, Okawa ER, et al. 2008. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J. Natl. Cancer Inst. 100:940-49
29. Theissen J, Oberthuer A, Hombach A, et al. 2014. Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma. Genes Chromosomes Cancer 53(8):639-49
30. De Preter K, Vermeulen J, Brors B, et al. 2010. Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature. Clin. Cancer Res. 16:1532-41
31. Westermann F, Muth D, Benner A, et al. 2008. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas. Genome Biol. 13;9(10):R1509
32. Bilke S, Chen QR, Westerman F, et al. 2005. Inferring a tumor progression model for neuroblastoma from genomic data. J. Clin. Oncol. 23:7322-31
33. Hansford LM, ThomasWD, Keating JM, et al. 2004. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification. Proc. Natl. Acad. Sci. USA 101:12664-69
34. WeissWA, Aldape K, Mohapatra G, et al. 1997. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16:2985-95
35. Schramm A, Koster J, Marschall T, et al. 2013. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-Amplified neuroblastoma. Int. J. Cancer 132:E106-15
36. Stallings RL. 2009. MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr. Pharm. Des. 15:456-62
37. Valentijn LJ, Koster J, Haneveld F, et al. 2012. A functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc. Natl. Acad. Sci. USA 109(47):19190-95
38. Shohet JM, Ghosh R, Coarfa C, et al. 2011. A genome-wide search for promoters that respond to increasedMYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma. Cancer Res. 71:3841-51
39. Huang M, Weiss WA. 2013. Neuroblastoma and MYCN. Cold Spring Harb. Perspect. Med. 3:a014415
40. Wakamatsu Y, Watanabe Y, Nakamura H, Kondoh H. 1997. Regulation of the neural crest cell fate by N-myc: promotion of ventral migration and neuronal differentiation. Development 124:1953-62
41. Van MaerkenT, Ferdinande L, Taildeman J, et al. 2009. Antitumor activity of the selectiveMDM2antagonist nutlin-3 against chemoresistant neuroblastoma with wild-Type p53. J. Natl. Cancer Inst. 101:1562-74
42. Barbieri E, Mehta P, Chen Z, et al. 2006. MDM2 inhibition sensitizes neuroblastoma to chemotherapyinduced apoptotic cell death. Mol. Cancer Ther. 5:2358-65
43. Evageliou NF, Hogarty MD. 2009. Disrupting polyamine homeostasis as a therapeutic strategy for neuroblastoma. Clin. Cancer Res. 15:5956-61
44. Bagatell R, Norris R, Ingle AM, et al. 2014. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Pediatr. Blood Cancer 61:833-39
45. Di Giannatale A, Dias-GastellierN, Devos A, et al. 2014. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study. Eur. J. Cancer 50:170-77
46. Maris JM. 2010. Recent advances in neuroblastoma. N. Engl. J. Med. 362:2202-11
47. Ardini E, Magnaghi P, Orsini P, et al. 2010. Anaplastic lymphoma kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy. Cancer Lett. 299:81-94
48. Mosse YP, Laudenslager M, Longo L, et al. 2008. Identification of ALK as amajor familial neuroblastoma predisposition gene. Nature 455:930-35
49. Minuti G, D'Incecco A, Landi L, Cappuzzo F. 2014. Protein kinase inhibitors to treat non-small-cell lung cancer. Expert Opin. Pharmacother. 15(9):1203-13
50. Ulivi P, Zoli W, Capelli L, et al. 2013. Target therapy in NSCLC patients: relevant clinical agents and tumour molecular characterisation. Mol. Clin. Oncol. 1:575-81
51. Reiff T, Huber L, Kramer M, et al. 2011. Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition. Development 138:4699-708
52. Wang M, Zhou C, SunQ, et al. 2013. ALK amplification and protein expression predict inferior prognosis in neuroblastomas. Exp. Mol. Pathol. 95:124-30
53. Schulte JH, Lindner S, Bohrer A, et al. 2013. MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene 32:1059-65
54. Mosse YP, Laudenslager M, Khazi D, et al. 2004. Germline PHOX2B mutation in hereditary neuroblastoma. Am. J. Hum. Genet. 75:727-30
55. TrochetD, Bourdeaut F, Janoueix-Lerosey I, et al. 2004. Germlinemutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am. J. Hum. Genet. 74:761-64
56. PeiD, LutherW, WangW, et al. 2013. Distinct neuroblastoma-Associated alterations of PHOX2B impair sympathetic neuronal differentiation in zebrafish models. PLOS Genet. 9:e1003533
57. Butler Tjaden NE, Trainor PA. 2013. The developmental etiology and pathogenesis of Hirschsprung disease. Transl. Res. 162:1-15
58. Di Lascio S, Bachetti T, Saba E, et al. 2013. Transcriptional dysregulation and impairment of PHOX2B auto-regulatorymechanism induced by polyalanine expansion mutations associated with congenital central hypoventilation syndrome. Neurobiol. Dis. 50:187-200
59. Wang W, Zhong Q, Teng L, et al. 2013. Mutations that disrupt PHOXB interaction with the neuronal calcium sensor HPCAL1 impede cellular differentiation in neuroblastoma. Oncogene 33(25):3316-24
60. Bachetti T, Di Paolo D, Di Lascio S, et al. 2010. PHOX2B-mediated regulation of ALK expression: in vitro identification of a functional relationship between two genes involved in neuroblastoma. PLOS ONE 1:5(10)
61. Burney MJ, Johnston C, Wong KY, et al. 2013. An epigenetic signature of developmental potential in neural stem cells and early neurons. Stem Cells 31:1868-80
62. Rada-Iglesias A, Bajpai R, Prescott S, et al. 2012. Epigenomic annotation of enhancers predicts transcriptional regulators of human neural crest. Cell Stem Cell 11:633-48
63. ErogluB, WangG, TuN, et al. 2006. Critical role of Brg1 member of the SWI/SNFchromatin remodeling complex during neurogenesis and neural crest induction in zebrafish. Dev. Dyn. 235:2722-35
64. Martins-Taylor K, Schroeder DI, LaSalle JM, et al. 2012. Role of DNMT3B in the regulation of early neural and neural crest specifiers. Epigenetics 7:71-82
65. OstlerKR, Yang Q, Looney TJ, et al. 2012. TruncatedDNMT3BisoformDNMT3B7suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma. Cancer Res. 72:4714-23
66. Newhart A, Rafalska-Metcalf IU, Yang T, et al. 2012. Single-cell analysis of Daxx and ATRX-dependent transcriptional repression. J. Cell Sci. 125:5489-501
67. Cheung NK, Zhang J, Lu C, et al. 2012. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA 307:1062-71
68. MaL, Young J, Prabhala H, et al. 2010. miR-9, a MYC/MYCN-Activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 12:247-56
69. Molenaar JJ, Domingo-Fernandez R, Ebus ME, et al. 2012. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat. Genet. 44(11):1199-206
70. Mestdagh P, Bostrom AK, Impens F, et al. 2010. The miR-17-92 microRNA cluster regulates multiple components of the TGF-beta pathway in neuroblastoma. Mol. Cell 40:762-73
71. Hamilton MP, Rajapakshe K, Hartig SM, et al. 2013. Identification of a pan-cancer oncogenicmicroRNA superfamily anchored by a central core seed motif. Nat. Commun. 4:2730:1-13
72. Buechner J, EinvikC. 2012. N-myc and noncoding RNAs in neuroblastoma. Mol. Cancer Res. 10(10):1243-53
73. Ara T, Nakata R, Sheard MA, et al. 2013. Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. Cancer Res. 73:3852-64
74. Liu D, Song L, Wei J, et al. 2012. IL-15 protects NKT cells from inhibition by tumor-Associated macrophages and enhances antimetastatic activity. J. Clin. Invest. 122:2221-33
75. Schleiermacher G, Mosseri V, London WB, et al. 2012. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br. J. Cancer 107:1418-22
76. Brodeur GM, Seeger RC, Barrett A, et al. 1988. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J. Clin. Oncol. 6:1874-81
77. Owens C, IrwinM. 2012. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments. Crit. Rev. Clin. Lab. Sci. 49:85-115
78. Cohn SL, Pearson AD, London WB, et al. 2009. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol. 27:289-97
79. Morgenstern DA, Baruchel S, IrwinMS. 2013. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J. Pediatr. Hematol. Oncol. 35:337-47
80. Castel V, Segura V, Berlanga P. 2013. Emerging drugs for neuroblastoma. Expert Opin. Emerg. Drugs 18:155-71
81. Heczey A, Louis CU. 2013. Advances in chimeric antigen receptor immunotherapy for neuroblastoma. Discov. Med. 16:287-94
82. BakerDL, SchmidtML, Cohn SL, et al. 2010. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N. Engl. J. Med. 363:1313-23
83. Hero B, SimonT, Spitz R, et al. 2008. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J. Clin. Oncol. 26:1504-10
84. RubieH, De Bernardi B, Gerrard M, et al. 2011. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. J. Clin. Oncol. 29:449-55
85. Bagatell R, Beck-Popovic M, London WB, et al. 2009. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J. Clin. Oncol. 27:365-70
86. De Bernardi B, Mosseri V, RubieH, et al. 2008. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. Br. J. Cancer 99:1027-33
87. Matthay KK, Perez C, Seeger RC, et al. 1998. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J. Clin. Oncol. 16:1256-64
88. Nickerson HJ, Matthay KK, Seeger RC, et al. 2000. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J. Clin. Oncol. 18:477-86
89. Yu AL, Gilman AL, Ozkaynak MF, et al. 2010. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363:1324-34
90. Endres S. 2014. Long-Term infusion of ch14-18/CHO combined with s.c. interleukin-2 applied in a single center treatment program effectively stimulates anti-neuroblastoma activity with reduced pain in high-risk neuroblastoma patients. Presented at Advances in Neuroblastoma Res. Conf. (ANR2014), Cologne.
91. Ladenstein R. 2014. Myeloablative therapy (MAT) and immunotherapy (IT) with ch14.18/CHO for high risk neuroblastoma: update and news of randomised results from the HR-NBL1/SIOPEN trial. Presented at Advances in Neuroblastoma Res. Conf. (ANR2014), Cologne
92. SchmidtM, Simon T, Hero B, et al. 2008. The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur. J. Cancer 44:1552-58
93. Matthay KK, Edeline V, Lumbroso J, et al. 2003. Correlation of early metastatic response by 123Imetaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J. Clin. Oncol. 21:2486-91
94. Beiske K, Burchill SA, Cheung IY, et al. 2009. Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.Br. J. Cancer 100:1627-37
95. Modak S. 2014. Generation and administration of autologous T cells transduced with a 3rd generation GD2 chimeric antigen receptor for patients with relapsed or refractory neuroblastoma. Presented at Advances in Neuroblastoma Res. Conf. (ANR2014), Cologne